Shots:
The P-III (evERA Breast Cancer) trial evaluated giredestrant + everolimus vs SoC ET + everolimus in ER+, HER2-, LA/M breast cancer pts previously treated with CDK4/6 inhibitors & endocrine therapy (ET) in adj. or LA/M settings
Trial met its co-1EPs of improved PFS in both the ITT & ESR1-mutated populations, while OS showed a…
